Movement Alert｜PHARMARON Rises 7.57% in Regular Trading, Board Reviewing H1 Results Amid Broad CXO Sector Rally

Market Focus

Aug 20

On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.

On the news front, the company's board convened today to review and approve its interim results for the first half of the year. Previously, PHARMARON guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New order signings grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%. Attributable net profit is expected to increase 4%-10%, reflecting strong earnings visibility.

Meanwhile, the CXO sector rallied broadly, with peers GenScript Biotech up 10.9%, XtalPi up 11.96%, Insilico up 8.27%, and WuXi Biologics up 3.67%. Sustained industry prosperity combined with concentrated H1 earnings delivery is accelerating sector valuation recovery. Additionally, JPMorgan recently increased its stake in PHARMARON by approximately 1.29 million shares at around 22.11 HKD per share, signaling institutional confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1141097569"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1141097569\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1141097569?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 09:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1141097569","market":"us","top_or_hot":-1,"title":"Movement Alert｜PHARMARON Rises 7.57% in Regular Trading, Board Reviewing H1 Results Amid Broad CXO Sector Rally","media":"Market Focus","content":"<p><p>On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.</p><p>On the news front, the company's board convened today to review and approve its interim results for the first half of the year. Previously, PHARMARON guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New order signings grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%. Attributable net profit is expected to increase 4%-10%, reflecting strong earnings visibility.</p><p>Meanwhile, the CXO sector rallied broadly, with peers GenScript Biotech up 10.9%, XtalPi up 11.96%, Insilico up 8.27%, and WuXi Biologics up 3.67%. Sustained industry prosperity combined with concentrated H1 earnings delivery is accelerating sector valuation recovery. Additionally, JPMorgan recently increased its stake in PHARMARON by approximately 1.29 million shares at around 22.11 HKD per share, signaling institutional confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜PHARMARON Rises 7.57% in Regular Trading, Board Reviewing H1 Results Amid Broad CXO Sector Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜PHARMARON Rises 7.57% in Regular Trading, Board Reviewing H1 Results Amid Broad CXO Sector Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 09:36</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.</p><p>On the news front, the company's board convened today to review and approve its interim results for the first half of the year. Previously, PHARMARON guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New order signings grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%. Attributable net profit is expected to increase 4%-10%, reflecting strong earnings visibility.</p><p>Meanwhile, the CXO sector rallied broadly, with peers GenScript Biotech up 10.9%, XtalPi up 11.96%, Insilico up 8.27%, and WuXi Biologics up 3.67%. Sustained industry prosperity combined with concentrated H1 earnings delivery is accelerating sector valuation recovery. Additionally, JPMorgan recently increased its stake in PHARMARON by approximately 1.29 million shares at around 22.11 HKD per share, signaling institutional confidence.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03759","symbol_name":"康龙化成","start_time":0,"source_url":"","article_id":"1141097569","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1141097569","pubTimestamp":1787189775,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.On the news front, the company's board convened today to review and...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03759":"康龙化成"},"translate_title":"走势警报|康龙化成常规交易上涨 7.57%，董事会在 CXO 板块普遍上涨的情况下审查上半年业绩","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03759":1},"content_text":"On August 20, PHARMARON rose 7.57% in regular trading, trading at 33.3 HKD/share, with turnover of approximately 50.68 million HKD.On the news front, the company's board convened today to review and approve its interim results for the first half of the year. Previously, PHARMARON guided H1 revenue of 7.472 billion to 7.665 billion yuan, representing year-over-year growth of 16%-19%. New order signings grew over 30% year-over-year, with small molecule CDMO new orders surging more than 50%. Attributable net profit is expected to increase 4%-10%, reflecting strong earnings visibility.Meanwhile, the CXO sector rallied broadly, with peers GenScript Biotech up 10.9%, XtalPi up 11.96%, Insilico up 8.27%, and WuXi Biologics up 3.67%. Sustained industry prosperity combined with concentrated H1 earnings delivery is accelerating sector valuation recovery. Additionally, JPMorgan recently increased its stake in PHARMARON by approximately 1.29 million shares at around 22.11 HKD per share, signaling institutional confidence.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,movement","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}